The three main political party leaders in the UK have all praised the HIV prevention drug PrEP, during a Q&A for GT (Gay Times) Magazine.
17 hours ago | Pink News
The science is now clear: oral pre-exposure prophylaxis (PrEP) with a coformulation of tenofovir disoproxil fumarate and emtricitabine (Truvada) significantly reduces the risk of HIV infection among individuals at high risk of HIV infection. The news that PrEP has shown consistent efficacy among those who take it as prescribed should be a cause for celebration, and galvanise action to ensure access to PrEP for those who could benefit the most.
17 April 2015 | The Lancet
Are condoms over? No. The availability of new prevention options does not require us to abandon a tool that has been proven effective for decades. Let's move forward in the search for new prevention options without bashing the ones we have -- or those who promote them.
15 April 2015 | The Body
In December 2014 the Illinois Department of Public Health (IDPH) publicly unveiled a program aimed at increasing access to the drug Truvada for pre-exposure prophylaxis (PrEP) to help HIV-negative people remain uninfected. But shortly after Governor Bruce Rauner took office, he issued an Executive Order that halted all “nonessential” spending in Illinois, which included PrEP4Illinois.
12 April 2015 | AIDS Chicago
Serodiscordant couples (where one partner is HIV negative and the other is HIV positive) are often thought to be at “high risk” of HIV transmission. However, new understandings of the biology of HIV transmission and the emergence of new HIV prevention options mean that the HIV transmission risk within these couples can be reduced to very low, even negligible levels.
07 April 2015 | CATIE
National survey finds providers’ perspectives lag behind PrEP guidelines: The survey was the first to be conducted since the U.S. Public Health Service released detailed PrEP guidelines in May 2014. In the Web-based survey fewer than half of 324 practitioners, most of them HIV specialists, fewer than half reported being “very likely” to prescribe PrEP to their patients who are high-risk heterosexuals or people who use intravenous drugs. For some other prime candidates—HIV-negative men whose male partners have the virus—79 percent of providers reported being very likely to prescribe the regimen.
07 April 2015 | Group Health Research Institute
The Centers for Disease Control and Prevention will lead new programs totaling more than $185 million in HIV prevention funding for men who have sex with men (MSM) and transgender people, with a particular focus on addressing the needs of MSM of color. Up to $125 million will help state and local health departments expand the use of two new, powerful HIV prevention strategies: pre-exposure prophylaxis (PrEP) and engaging more people in HIV care.
07 April 2015 | CDC press release
Positively UK welcomes the findings from PROUD and IPERGAY studies, which demonstrate the high effectiveness of usingPre-Exposure Prophylaxis (PrEP) as an effective tool for HIV prevention and promoting the health of gay men and men who have sex with men. Positively UK joins other UK based HIV and LGBT organisations in urging the NHS to speed up the approval process and make PrEP available.
01 April 2015 | Positively UK
Take a pill daily and prevent the contraction of HIV 99 percent of the time. That is the narrative presented to many young men who have sex with men (MSM) by their peers regarding pre-exposure prophylaxis (PrEP). And, as is normally the case with anything framed in such a simple manner, the nuances of treatment fall through the cracks. It is unwise to herald PrEP as the key to freeing a generation from HIV. It is merely one piece of a larger effort. Not only is PrEP not for everyone, but public health activists face political obstacles similar to those hurled at advocates of birth control.
01 April 2015 | Yale Daily News
As a clinician who has witnessed the devastating impact of the HIV/AIDS epidemic since the 1980s, Sheena McCormack is enthusiastic about her latest project, the UK Medical Research Council (MRC) PROUD study. As lead investigator, she has been investigating the effect of pre-exposure prophylaxis (PrEP) to protect against HIV infection in high-risk men who have sex with men (MSM). PROUD has shown that PrEP reduces new HIV infections by 86%.
28 March 2015 | The Lancet